An atypical Spitz tumor (AST) sits in a gray zone between a clearly harmless mole and melanoma, and that uncertain position makes it one of the most debated diagnoses in dermatopathology. These melanocytic lesions carry some worrying features under the microscope but lack the full hallmarks of cancer, and even expert pathologists frequently disagree on exactly where to draw the line. The good news for most patients is that long-term outcomes are overwhelmingly favorable, but getting to that reassurance often involves a confusing journey through biopsies, re-excisions, and sometimes additional procedures whose value remains genuinely controversial.
Why Diagnosis Is So Contentious
Spitz tumors exist on a spectrum. At one end is the classic Spitz nevus, a benign growth made up of large spindle-shaped or egg-shaped melanocytes that can alarm a pathologist at first glance but behaves harmlessly. At the other end is spitzoid melanoma, a true cancer that shares surface-level similarities with the benign version. The atypical Spitz tumor occupies the middle ground, showing some features suggestive of melanoma but not enough to make a definitive diagnosis of malignancy.
The practical problem is that pathologists looking at the same slide often reach different conclusions. A landmark study submitted 17 spitzoid lesions to a panel of expert pathologists, and in only one case did six or more of them agree on a single diagnostic category. Some lesions that ultimately proved fatal had been called benign by most observers, while others labeled melanoma by the majority turned out to behave innocuously.1Human Pathology. Atypical spitz nevi/tumors: Lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome This disagreement is not a sign of incompetence. It reflects the genuine biological ambiguity of these tumors, which lack clear-cut objective criteria separating them from melanoma.2PubMed. Spitz melanocytic tumours – a review
Under the microscope, pathologists look for a cluster of architectural and cellular features to guide classification. Benign Spitz nevi tend to be symmetrical and dome-shaped, show epidermal thickening, contain small pink globules called Kamino bodies, and have melanocytes that mature (get smaller and less active) as they extend deeper into the skin. Melanoma, by contrast, tends to be asymmetric, poorly circumscribed, and shows atypical mitotic figures deep in the dermis, high-grade cellular atypia, and a failure to mature with depth.3Modern Pathology. Atypical Spitz Tumor: Diagnosis, Treatment, and Prognosis An AST has some of these alarming features but not the full constellation, leaving the pathologist in an honest state of uncertainty.
What Atypical Spitz Tumors Look Like Clinically
Most ASTs show up as a firm plaque or nodule on the skin, and they can be pigmented or flesh-colored. When dermatologists examine them with dermoscopy (a handheld magnification tool that reveals structures invisible to the naked eye), the most common finding is a multicomponent pattern, meaning several different structural elements are mixed together without a dominant organizing theme.4PubMed Central. Clinical and dermoscopic features of Atypical Spitz Tumors: a multi-center, retrospective, case-control study A multicenter study with 16 years of follow-up confirmed that the multicomponent pattern was the single most frequent dermoscopic appearance, found in about a third of cases, followed by homogeneous and nonspecific patterns. Among amelanotic (non-pigmented) ASTs, a distinctive pattern of coiled vessels distributed uniformly across the lesion appeared in roughly two-thirds of cases.5Clinical and Experimental Dermatology. Atypical Spitz tumours: an epidemiological, clinical and dermoscopic multicentre study with 16 years of follow‐up
Nodularity and the presence of white lines on dermoscopy were the two features most strongly linked to an AST diagnosis after statistical adjustment, while a pigmented starburst or globular pattern typical of classic Spitz nevi made a benign diagnosis much more likely.4PubMed Central. Clinical and dermoscopic features of Atypical Spitz Tumors: a multi-center, retrospective, case-control study In practice, this means that a growing, firm, nodular lesion without the reassuring starburst pattern deserves a biopsy, especially in a child or young adult.
Molecular Genetics Set Spitz Tumors Apart
One of the most important advances in understanding atypical Spitz tumors has been discovering that they are driven by a fundamentally different set of genetic alterations than common moles or typical melanoma. Ordinary moles and conventional melanomas usually carry mutations in BRAF, NRAS, or loss of a gene called NF1. Spitz tumors, by contrast, tend to harbor HRAS mutations, loss of the BAP1 gene (often alongside BRAF mutations), or fusions involving kinase genes such as ALK, ROS1, NTRK1, BRAF, RET, and MET.6Pathology. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy These kinase fusions effectively jam a growth-signaling switch in the “on” position, pushing melanocytes to proliferate.
These fusions are remarkably common across the entire Spitz spectrum. A study analyzing 140 spitzoid neoplasms identified kinase fusions in about 55% of Spitz nevi, 56% of atypical Spitz tumors, and 39% of spitzoid melanomas.7Nature Communications. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas The fact that the fusion rate is nearly identical between benign nevi and ASTs underscores an important point: the fusion alone does not determine whether a tumor will behave aggressively. Additional genetic hits are needed to push a Spitz tumor toward malignancy.
Among specific fusions, NTRK gene fusions have drawn particular attention because of the availability of targeted drugs. In one study of ASTs, NTRK fusions were found in about 9% of cases, with NTRK1 fusions far outnumbering NTRK3 fusions. Pan-TRK immunostaining proved an effective initial screening tool for identifying cases that warranted molecular confirmation.8PubMed Central. NTRK Gene Fusion Detection in Atypical Spitz Tumors
Biomarkers That Help Sort Risk
Because morphology alone cannot reliably predict how an AST will behave, researchers have invested heavily in finding molecular markers that flag the truly dangerous cases. Two areas have shown the most promise so far: TERT promoter mutations and chromosomal copy number changes detected by a technique called fluorescence in situ hybridization (FISH).
TERT promoter mutations are alterations that cause cells to maintain their telomeres, essentially letting them divide indefinitely, a hallmark of cancer. In spitzoid tumors, these mutations appear to be a powerful red flag. One study found TERT promoter mutations in every patient whose spitzoid tumor went on to spread to distant organs but in none of the patients with favorable outcomes, making it the single strongest predictor of dangerous behavior in the cohort.9PubMed Central. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms A broader review confirmed that among atypical spitzoid neoplasms, finding a TERT promoter mutation strongly supports reclassifying the lesion as spitzoid melanoma rather than a borderline tumor.10PubMed. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis
FISH testing looks for gains or losses of specific chromosomal regions. Among atypical Spitz tumors, a deletion of both copies of a region on chromosome 9 (9p21) is strongly associated with aggressive behavior and death from disease. Gains at two other chromosomal loci (6p25 and 11q13) also carry elevated risk, though less dramatically.11American Journal of Surgical Pathology. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations ASTs with more benign behavior tend to show at most one or two chromosomal gains or losses, while those that behave aggressively accumulate several.12Frontiers in Oncology. The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification
FISH is useful but imperfect. A study comparing standard FISH probes with a broader genome-wide analysis found that the standard probes missed some genuinely aggressive cases, including one fatal metastatic AST. A comprehensive chromosomal analysis offered better sensitivity and specificity.13The American Journal of Surgical Pathology. Copy Number Variations and Clinical Outcome in Atypical Spitz Tumors As genomic technologies become cheaper and faster, more thorough testing may eventually replace the targeted FISH panels currently in use.
Immunohistochemistry offers another layer of information. A scoring system combining p16, Ki-67, and HMB45 staining has shown the ability to separate benign Spitz lesions and ASTs (which scored below a threshold) from spitzoid melanomas (which scored above it), providing a relatively accessible tool for pathology labs that may not have molecular testing readily available.14Pathology – Research and Practice. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors
Surgical Treatment and Margins
Once an AST is diagnosed on biopsy, the standard recommendation is surgical re-excision to ensure the entire lesion has been removed. The question that has shifted over time is how wide those margins need to be. Historically, some clinicians treated ASTs with the wide margins used for melanoma, which can mean removing a centimeter or more of surrounding skin. That approach leaves a larger scar and can be especially burdensome in children, who account for a large proportion of AST diagnoses.
Current consensus has moved toward narrower margins. A single-center retrospective review found that narrow-margin excision of ASTs was commonly used and associated with excellent short- to mid-term cancer outcomes and low surgical complications, consistent with consensus recommendations favoring more conservative surgery in children.15PubMed. Narrow-Margin Excision of Atypical Spitz Tumors: A Single-Center Retrospective Review The rationale is straightforward: if the prognosis is overwhelmingly favorable regardless of margin width, wider surgery imposes unnecessary morbidity without a clear benefit.
The Sentinel Lymph Node Puzzle
Perhaps no aspect of AST management generates more debate than sentinel lymph node biopsy (SLNB). This procedure, in which the first lymph node draining the tumor site is removed and examined for tumor cells, is a standard staging tool in melanoma. In melanoma, a positive sentinel node carries clear prognostic weight and can guide decisions about further treatment. In ASTs, the picture is far murkier.
ASTs have a surprisingly high rate of sentinel node positivity. A systematic review found a pooled positive rate of about 35% among patients who underwent the procedure.16PubMed Central. Sentinel Lymph Node Biopsy in Atypical Spitz Tumor: A Systematic Review Individual studies have reported rates ranging from roughly 26% to 47%.17PubMed. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors 18PubMed. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution These numbers are strikingly high compared to what you would see in typical thin melanomas.
The critical finding, however, is that a positive sentinel node in an AST does not seem to carry the same ominous implications as in melanoma. In the 67-patient series cited above, all 27 patients with positive sentinel nodes were alive and disease-free after a median follow-up of nearly four years.18PubMed. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution Another study following 40 patients with problematic spitzoid tumors for a mean of nearly five years found that none of them developed metastases beyond the regional lymph node basin, regardless of sentinel node status, leading the authors to conclude that SLNB may not be a reliable prognostic test for these tumors.17PubMed. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors
This disconnect has led many experts to question whether SLNB should be routinely performed for ASTs. The procedure carries surgical risks and anxiety, and if a positive result does not change the outcome or guide treatment differently, its value becomes harder to justify. Some institutions still offer it, particularly when the histology is ambiguous enough that reclassification as spitzoid melanoma remains a possibility. Others have moved away from it entirely for lesions that are clearly in the AST category rather than on the cusp of melanoma.
Long-Term Prognosis
The single most reassuring fact about atypical Spitz tumors is that the vast majority of patients do well. A study with a median follow-up of over nine years found that only one patient with an AST developed distant metastasis, and that patient also had a separate intermediate-thickness melanoma, complicating the picture. The authors characterized ASTs as having “minimal lethal potential” but acknowledged a moderate risk of tumor cells reaching regional lymph nodes.19PubMed Central. Long-term outcome of Spitz-type melanocytic tumors
A case report illustrating this pattern followed a girl diagnosed with an AST and lymph node involvement at age 10 who showed no recurrence after 20 years of follow-up.20The American Journal of Dermatopathology. Atypical Spitz Tumor (Spitz Melanocytoma) With Lymph Node Metastasis and Long-Term Clinical Follow-Up That same report noted an important caveat: childhood melanomas, which can be confused with ASTs, sometimes carry TERT promoter mutations and behave far more aggressively. This reinforces why molecular testing for TERT matters so much in borderline cases.
The emerging consensus is that ASTs as a category carry very low lethal risk after adequate excision. The genuine danger lies in cases that are actually spitzoid melanomas misclassified as ASTs, which is why the diagnostic tools described above continue to evolve.
How Age Affects the Picture
ASTs behave somewhat differently in children and adults, though the outcomes are broadly favorable in both groups. A 20-year cohort study found that average tumor thickness was substantially greater in patients 18 and younger (about 2.3 mm) compared with adults over 40 (about 0.9 mm), and mitotic activity was also much higher in younger patients.21Skin Health and Disease. Atypical Spitz tumours across age groups: clinicopathological features, management strategies and long-term outcomes in a 20-year retrospective cohort study Paradoxically, these features that would be alarming in a conventional melanoma did not translate into worse outcomes in children. Sentinel node positivity was higher in pediatric patients (42%) than in adults (9%), yet no distant metastases or melanoma-related deaths occurred in either group. Five-year recurrence-free survival was 100% for patients under 40 and 98% for those over 40.
The only local recurrence in the entire cohort was in a 47-year-old patient whose tumor was later reclassified as conventional melanoma, again underscoring that misclassification rather than inherent AST biology is the real threat.21Skin Health and Disease. Atypical Spitz tumours across age groups: clinicopathological features, management strategies and long-term outcomes in a 20-year retrospective cohort study For parents of a child diagnosed with an AST, these data are particularly meaningful. Children’s ASTs often look more worrisome under the microscope than adults’ do, but they almost never progress to life-threatening disease.
Targeted Therapy and Future Directions
Because Spitz tumors are driven by identifiable kinase fusions, they are theoretically vulnerable to drugs designed to block those specific pathways. This possibility has already been explored in rare cases where surgery is not straightforward. A young child with unresectable, clustered Spitz nevi carrying a ROS1 fusion was treated with crizotinib, a kinase inhibitor. After 20 weeks of treatment, lesions around the eye, scalp, and ear had flattened completely to faint pigmented spots, with no new lesions appearing.22JAMA Dermatology. Evaluation of Crizotinib Treatment in A Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi While this was a Spitz nevus rather than an AST, the principle is the same: when the molecular driver is known, a matched drug can shut down growth.
For ASTs specifically, targeted therapy is not standard practice because surgery alone is almost always curative. But the approach could become relevant in hypothetical scenarios involving unresectable or recurrent lesions, or in the rare case where an AST turns out to harbor features closer to melanoma. The growing catalog of kinase fusions identified in Spitz tumors, including ALK, ROS1, NTRK1, BRAF, RET, and MET, means that a drug or clinical trial may be available for each molecular subtype.23PubMed Central. An update on molecular alterations in melanocytic tumors with emphasis on Spitzoid lesions This molecular diversity also reinforces a broader shift in oncology: classifying tumors by their genetic drivers rather than purely by where they arise or how they look under the microscope.
Living with Diagnostic Uncertainty
For patients and families, the hardest part of an AST diagnosis is often the uncertainty itself. Being told you have a tumor that “might be cancer but probably isn’t” is not especially comforting, and the chain of events that follows, re-excision, possible sentinel node biopsy, years of follow-up visits, can feel disproportionate to what is almost always a benign course. The emotional weight of watching and waiting should not be underestimated, particularly for parents of young children.
Follow-up protocols vary by institution. Some centers recommend skin checks every six months for several years, while others adopt a less intensive schedule once the excision margins are clear and molecular testing (if performed) is reassuring. There is no universally agreed-upon surveillance protocol, reflecting the broader absence of consensus on how to manage these lesions beyond the initial surgery. Dermatologists tend to tailor the follow-up to the individual case, factoring in the patient’s age, the histological features, any molecular results, and the sentinel node status if one was performed.
One practical piece of advice worth emphasizing: patients with a history of AST appear to have an elevated risk of developing a separate melanoma later in life.19PubMed Central. Long-term outcome of Spitz-type melanocytic tumors This does not mean the AST itself transformed; it means the patient may have a general susceptibility to melanocytic proliferation that warrants ongoing vigilance. Lifelong skin surveillance, sun protection, and self-examination of moles remain sensible habits for anyone who has been through an AST diagnosis, long after the original lesion has been excised and forgotten.